Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06040099 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Study acronym: EMERALD-Y90
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Jul 1, 2026 to May 27, 2027 Primary completion date changed from estimate of Jul 1, 2026 to Jun 30, 2026 · Eligibility criteria expanded, about 19 words · Secondary endpoints: details revised at 3 of 4 entries · 1 more Show 4 more changesShow less
    • Primary completion date changed from estimate of Jul 1, 2026 to Jun 30, 2026
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv18
  3. Enrollment target: 56 to 58 Primary completion date: Oct 23, 2026 to Jul 1, 2026 · Completion date: Jan 13, 2027 to Jul 1, 2026v17 Show 2 more changesShow less
    • Primary completion date: Oct 23, 2026 to Jul 1, 2026
    • Completion date: Jan 13, 2027 to Jul 1, 2026
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 60 to confirmed 56 · Study sites: 25 to 21 · Completion date: Oct 23, 2026 to Jan 13, 2027v16 Show 3 more changesShow less
    • Enrollment target: estimated 60 to confirmed 56
    • Study sites: 25 to 21
    • Completion date: Oct 23, 2026 to Jan 13, 2027
  5. Re-verified, no change to tracked fieldsv15
Show 13 earlier versionsHide 13 earlier versions
  1. Enrollment target: 100 to 60 Eligibility criteria expanded, about 40 words · Secondary endpoints: details revised at 1 of 4 entries · Study description revisedv14 Show 3 more changesShow less
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv13
  3. Site details revised at 1 of 25 sitesv12
  4. Site details revised at 1 of 25 sitesv11
  5. Site details revised at 4 of 25 sitesv10
  6. Eligibility criteria shortened, about 2 wordsv9 See this version in full on ClinicalTrials.gov ↗
  7. Site details revised at 1 of 25 sitesv8
  8. Site details revised at 2 of 25 sitesv7
  9. Study sites: 22 to 25 Primary and study completion dates: Jul 23, 2026 to Oct 23, 2026v6 Show 1 more changeShow less
    • Primary and study completion dates: Jul 23, 2026 to Oct 23, 2026
  10. Study sites: 21 to 22v5
  11. Study sites: 13 to 21 Primary and study completion dates: Sep 30, 2026 to Jul 23, 2026v4 Show 1 more changeShow less
    • Primary and study completion dates: Sep 30, 2026 to Jul 23, 2026
  12. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 13 · Start date changed from estimate of Jan 31, 2024 to Feb 13, 2024v3 Show 2 more changesShow less
    • Study sites: 0 to 13
    • Start date changed from estimate of Jan 31, 2024 to Feb 13, 2024
  13. Start date: Sep 30, 2023 to Jan 31, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Trial Details
NCT Number NCT06040099
Lead Sponsor AstraZeneca
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov